The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized trial

Diabetes Technology and Therapeutics

Volumn 8, Issue 6, 2006, Pages 636-643

  Singer, Gregory M ^a   Geohas, Jeff ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; BIGUANIDE DERIVATIVE; BIOTIN; BIOTIN PLUS CHROMIUM PICOLINATE; CHROMIUM PICOLINATE; DIACHROME; FRUCTOSAMINE; GLITAZONE DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL SUPPORT; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTILIPEMIC AGENTS; BIOTIN; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IRON CHELATING AGENTS; LIPID METABOLISM; MALE; MIDDLE AGED; PICOLINIC ACIDS; PILOT PROJECTS; VITAMIN B COMPLEX;

EID: 33845341453     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.8.636     Document Type: Article

References (23)

1. Song SH, Brown PM: Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 2004;21:238-245.
2. Colagiuri S, Cull CA, Holman RR: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes asscciated with improved outcomes?: UK Prospective Diabetes Study 61. Diabetes Care 2002;25:1410-1417.
3. Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342.
4. Cefalu WT, Hu FB: Role of chromium in human health and in diabetes. Diabetes Care 2004;27:2741-2751.
5. Fernadez-Mejia C: Pharmacological effects of biotin. J Nutr Biochem 2005;16:424-427.
6. Wang ZQ, Zhang XH, Cefalu WT: Chromium picolinate and biotin enhance glycogen synthesis and glycogen synthase gene expression in human skeletal muscle culture [abstract]. Diabetes Res Clin Pract 2000;50(Suppl 1):395.
7. Komorowski JR, de la Harpe J, Cefalu WT, Zhang XH, Wang ZQ, Greenberg D: JCR:LA-cp rats show improved lipid profiles in response to diets containing chromium picolinate and biotin [abstract-80]. In: SSIB Program. San Antonio, TX: Society for the Study of Ingestive Behavior, 2001:41.
8. Matthews JNS, Altman DG, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 1990;300:230-235.
9. Vuksan V, Stavro M, Sievenpiper J, Beljan-Zdravkovic U, Leiter L, Josse R, Xu Z: Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care 2000;23:1221-1226.
10. Vuksan V, Sievenpiper J, Koo V, Francis T, Beljan-Zdravkovic U, Xu Z, Vidgen E: American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med 2000;160:1009-1013.
11. Reaven GM: Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia and coronary heart disease. Am Heart J 1991;121:1283-1288.
12. Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 1999;83:25F-29F.
13. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults - findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
14. Cotton PA, Subar AF, Friday JE, Cook A: Dietary sources of nutrients among US adults, 1994 to 1996. J Am Diet Assoc 2004;104:921-930.
15. Anderson RA, Bryden NA, Polansky MM: Dietary chromium intake. Freely chosen diets, institutional diet, and individual foods. Biol Trace Elem Res 1992;32:117-121.
16. Rajpathak S, Rimm, EB, Li T, Morris JS, Stampfer M J, Willett WC, Hu FB: Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 2004;27:2211-2216.
17. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Randovancevic B: Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. Am Heart J 2005;149:632-636.
18. Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J: Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090-2095.
19. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
20. Meigs J, Nathan D, D'Agostino R, Wilson P: Fasting and post-challenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-1850.
21. Pyorala K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P: Glucose tolerance and coronary heart disease: Helsinki Policemen Study. J Chronic Dis 1979;32:729-745.
22. Jackson CA, Yudkin JS, Forrest RD: A comparison of the relationships of the glucose tolerance test and the glycated hemoglobin assay with diabetic vascular disease in the community: the Islington Diabetes Survey. Diabetes Res Clin Pract 1992;17:111-123.
23. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.